Prof Arnold Vulto speaks to ecancer at the 2019 Biosimilars Educational Advanced Masterclass for Pharmacists (P-BEAM) in Zurich about the sustainability of the biosimilar market.
He explains the factors that affect this market and that multi-winner tenders present the best outcome for the sustainability of the market.
Prof Vulto acknowledges that although biosimilars present the same efficacy and safety, there are differences - such as support, stability and combination partners.
ecancer's filming has been kindly supported by Amgen through the ecancer Global Foundation. ecancer is editorially independent and there is no influence over content.
If you would like to learn more about biosimilar medicines, please visit our free e-learning modules here.